ABHD3

Across TCGA pan-cancer cohorts, ABHD3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ABHD3 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ABHD3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ABHD3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, LGG, and STAD are the cancer types where ABHD3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	II,III,IV	0.122	0.685	.001	33	view →
LGG	OS	Median	All	0.148	0.909	<.001	12	view →
STAD	OS	Median	II,III,IV	0.152	0.660	.001	12	view →
LUSC	OS	Median	II,III,IV	0.181	0.732	.009	6	view →
UCEC	DFS	Median	All	0.953	0.627	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ABHD3–HNSC (DFS)

Open the HNSC breakdown →